Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV000002275 | SCV000448857 | pathogenic | Bietti crystalline corneoretinal dystrophy | 2017-04-27 | criteria provided, single submitter | clinical testing | The CYP4V2 c.1091-2A>G variant occurs in a canonical splice site (acceptor) and is therefore predicted to disrupt or distort the normal gene product. Across a selection of available literature, the c.1091-2A>G variant has been identified in 30 individuals with retinal atrophy, Bietti crystalline dystrophy, or retinitis pigmentosa, including in a homozygous state in five individuals and in a compound heterozygous state in 25 individuals. In addition, it was reported in a heterozygous state in five unaffected family members (Li et al. 2004; Xiao et al. 2011; Wang et al. 2012; Fu et al. 2013; Meng et al. 2014). The c.1091-2A>G variant was absent from 196 controls and is reported at a frequency of 0.00035 in the East Asian population of the Exome Aggregation Consortium. Based on the potential impact of splice acceptor variants and evidence from the literature, the c.1091-2A>G variant is classified as pathogenic for Bietti crystalline dystrophy. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Ocular Genomics Institute, |
RCV000002275 | SCV001573350 | pathogenic | Bietti crystalline corneoretinal dystrophy | 2021-04-08 | criteria provided, single submitter | research | The CYP4V2 c.1091-2A>G variant was identified in an individual with retinitis pigmentosa with a presumed recessive inheritance pattern. Through a review of available evidence we were able to apply the following criteria: PVS1, PM2, PM3. Based on this evidence we have classified this variant as Pathogenic. |
Labcorp Genetics |
RCV001851576 | SCV002229249 | pathogenic | not provided | 2024-10-21 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 8 of the CYP4V2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CYP4V2 are known to be pathogenic (PMID: 15042513, 25118264). This variant is present in population databases (rs199476183, gnomAD 0.06%). Disruption of this splice site has been observed in individual(s) with Bietti crystalline dystrophy and retinitis pigmentosa (PMID: 15042513). This variant is also known as IVS8-2A>G. ClinVar contains an entry for this variant (Variation ID: 2191). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Dept Of Ophthalmology, |
RCV003887849 | SCV004706595 | likely pathogenic | Retinal dystrophy | 2023-10-01 | criteria provided, single submitter | research | |
Juno Genomics, |
RCV000002275 | SCV005417748 | pathogenic | Bietti crystalline corneoretinal dystrophy | criteria provided, single submitter | clinical testing | PVS1_Strong+PM3_VeryStrong+PP1_Strong+PP4+PM2_Supporting | |
Sing |
RCV000002275 | SCV005881610 | likely pathogenic | Bietti crystalline corneoretinal dystrophy | 2025-02-05 | criteria provided, single submitter | clinical testing | Variant is predicted to cause LOF through splicing in a gene where LOF is a known cause of pathogenicity (PVS1). Variant is not found in gnomAD genomes and homozygous allele count in gnomAD exomes are less than 0 (PM2). |
OMIM | RCV000002275 | SCV000022433 | pathogenic | Bietti crystalline corneoretinal dystrophy | 2013-06-14 | no assertion criteria provided | literature only | |
Gene |
RCV000002275 | SCV000058224 | pathogenic | Bietti crystalline corneoretinal dystrophy | 2012-04-12 | no assertion criteria provided | curation | Converted during submission from pathologic to Pathogenic. |